TOP HEADLINES

Featured Story

Lexicon rockets up after a positive PhIII study sets up an NDA

Shares of Lexicon Pharmaceuticals soared 35% this morning after The Woodlands, TX-based biotech claimed a win in Phase III for one of its lead drugs. The biotech said that telotristat etiprate proved effective against rare cases of carcinoid syndrome, a condition triggered by neuroendocrine tumor cells that causes severe diarrhea.

Baxalta's first-of-its-kind bleeding drug lines up for FDA approval

Baxalta, recently spun out from Baxter, is charging toward its first drug approvals under a new identity, publishing positive results for a bleeding treatment awaiting word from the FDA.

Sorrento buys into biosimilars with a Chinese antibody deal

Sorrento Therapeutics, among many companies in the orbit of billionaire entrepreneur Patrick Soon-Shiong, is looking to take a spot in the growing market for knockoffs of the world's top-selling biotech medicines.

Bristol-Myers to collaborate on immuno-oncology studies

Bristol-Myers Squibb has signed on Northwestern University to partner on some early-stage immunotherapy trials.

AstraZeneca isn't giving up on brodalumab despite its links to suicide

Amgen shocked the industry in May when it cut ties with an AstraZeneca-partnered psoriasis treatment after spotting alarming rates of suicidal thoughts among patients taking the antibody. But its former collaborator is remaining optimistic about the once-promising treatment, tentatively moving toward an FDA filing.

MORE NEWS

From Our Sister Sites

FiercePharma Manufacturing

An Ohio company has gotten FDA approval for its epilepsy drug Spritam, which it claims is the first to use three-dimensional printing technology. Aprecia Pharmaceuticals says the 3D process produces a formulation of levetiracetam that rapidly disintegrates with a sip of liquid, making it easy to ingest for those who have trouble taking medication.

FierceDrugDelivery

Northwestern University announced that it has received a five-year, $17.5 million grant from the National Institutes of Health to study an implantable drug delivery system for the prevention of HIV. It's the latest application of drug delivery to solve the classic medical problem of adherence by developing a device that releases medication in a continuous and controlled manner for up to one year.